Nyrada Quarterly Activities Report & Appendix 4C 30 Jun 2022
Highlights: • Cholesterol-Lowering Program: – Nyrada’s PCSK9 inhibitor shown to block the early stages of atherosclerosis in a novel human… Read more
Highlights: • Cholesterol-Lowering Program: – Nyrada’s PCSK9 inhibitor shown to block the early stages of atherosclerosis in a novel human… Read more
July 20, 2022 Nyrada Inc. (ASX:NYR) released an announcement headed “Nyrada’s PCSK9 Inhibitor Evaluated in Novel Model of Atherosclerosis”. We… Read more
• Cholesterol-Lowering Program preclinical safety and toxicology studies remain on track to commence Q3 CY2022 • COVID-related lockdowns in Shanghai… Read more
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation that will be… Read more
• Brain Injury Program target revealed as versatile TRPC ion channels • NYR-BI02 is a potent blocker of three TRPC… Read more
The European Patent Office has issued a Notice of Intention to grant Nyrada’s patent application for novel compounds inhibiting PCSK9…. Read more
Highlights: • Brain Injury Program: – Exploratory study shows new lead drug candidate NYR-BI02 could be taken orally, offers potential… Read more
Nyrada Inc (ASX: NYR) is pleased to provide shareholders and the market generally with the attached presentation ahead of a… Read more
Nyrada Inc. (ASX: NYR) released an announcement about its new lead brain injury drug candidate NYR-BI02. The new drug shows… Read more